Washington University School of Medicine: Myelodysplastic Syndromes trials

The registry lists 31 Myelodysplastic Syndromes studies with Washington University School of Medicine as lead sponsor. 4 are open to participants now and 11 have results posted.

Early Phase 1 1Phase 1 17Phase 2 14No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)RecruitingNCT05483010Phase 2
• Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDSRecruitingNCT05434598Not applicable
• Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDSRecruitingNCT04986657Not applicable
• Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell TransplantRecruitingNCT04742634Phase 1/2
• Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)TerminatedNCT04582864Phase 2Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Azacitidine in Patients Undergoing Matched Unrelated Stem Cell TransplantationTerminatedNCT01747499Phase 1/2Results posted
• Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT01687400Phase 2Results posted
• Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating AgentsCompletedNCT01246076Phase 2Results posted
• Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling DonorsCompletedNCT01158118Phase 2Results posted
• LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)CompletedNCT00691938Phase 1/2Results posted
• Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic TransplantationTerminatedNCT00593645Phase 2Results posted
• A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic SyndromesCompletedNCT00384956Phase 2Results posted
• Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological MalignanciesCompletedNCT00241358Phase 1/2Results posted
• Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDSWithdrawnNCT04893915Phase 2
• AML/MDS Drug Sensitization by in Vivo Chemotherapy AdministrationActive, not recruitingNCT04263181
• CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic SyndromeActive, not recruitingNCT03572764Phase 1
• CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid LeukemiaCompletedNCT02995655Phase 1
• Azacitidine in Haploidentical Donor Hematopoietic Cell TransplantationTerminatedNCT02750254Phase 1
• Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
• Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
• Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic SyndromesCompletedNCT01913951Phase 1
• Study of Hypotensive Hematopoietic Malignancy Patients' USCOM ReadingsCompletedNCT01755000Not applicable
• Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell TransplantationCompletedNCT01700751Phase 1
• Azacitidine After Chemotherapy and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome Previously Treated With Donor Stem Cell TransplantCompletedNCT01390311Phase 1
• Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)CompletedNCT01065129Phase 1
• Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post TransplantCompletedNCT00986804Phase 1
• Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed DiseaseCompletedNCT00871702Phase 1
• Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT00671697Phase 1
• Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous TherapyTerminatedNCT00006220Phase 1/2